Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?

Future oncology (London, England) - 1 Dec 2013

Santini Daniele, Vincenzi Bruno, Venditti Olga, Dell'Aquila Emanuela, Frezza Anna Maria, Silletta Marianna, Guida Francesco Maria, Grasso Rosario Francesco, Silvestris Nicola, Lanzetta Gaetano, Tonini Giuseppe

Abstract excerpt

Sunitinib has previously been reported to be potentially effective in the treatment of malignant melanomas expressing c-KIT. Here we report on the case of a 77-year-old gentleman affected by a metastatic clear cell carcinoma of the kidney and a metastatic malignant melanoma with liver and lung metastases. Despite the negativity for CD117 and the absence of KIT amplification or mutations in the melanoma specimen,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Proto-Oncogene Proteins c-kit

Share to Pyrroles

Share to Skin Neoplasms

Share to Sunitinib

Source

Identifiers

PMID: 24295410
DOI: 10.2217/fon.13.170

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?PMID 24295410Read ↗

Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy.Semantic proximity Read ↗

Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.Semantic proximity Read ↗

Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.Semantic proximity Read ↗

Sunitinib therapy for melanoma patients with KIT mutations.Semantic proximity Read ↗

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.Semantic proximity Read ↗

Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.Semantic proximity Read ↗

Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience.Semantic proximity Read ↗

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.Semantic proximity Read ↗

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.Semantic proximity Read ↗

Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.Semantic proximity Read ↗

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.Semantic proximity Read ↗

A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.